pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$EBSEmergent BioSolutions Inc.

$EBS
Gaithersburg, MD, USupdated 21d ago

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
7
marketed
6
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(7)

pipeline depth7 products
Phase 3: 1Marketed: 6
1Phase 36Marketed
Marketed
Cyfendus
Anthrax
Marketed
anthrax immune globulin (human)
Anthrax
Marketed
anthrax vaccine
Anthrax
Marketed
botulism [Clostridium botulinum] [serotype A, B, C, D, E, F, G] (heptavalent) antitoxin [equine]
Botulism
Marketed
raxibacumab
Anthrax
Marketed
smallpox vaccine
Monkeypox
Phase 3
NP-028
Coronavirus Disease 2019 (COVID-19)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 1, 26SELLWilliams Paul Anthony· SVP, Products Business4,000 sh @ $8.44−$34K↗
routine RSU / option mechanics (6)
  • Mar 5, 26tax coverPAPA JOSEPH C · President and CEO37,055 sh
  • Mar 5, 26tax coverLINDAHL RICHARD S · EVP, Chief Financial Officer23,650 sh
  • Mar 5, 26tax coverLowry Simon C · SVP, R&D, CMO10,636 sh
  • Mar 5, 26tax coverHartzel William · SVP, Bioservices9,493 sh
  • Mar 5, 26tax coverWilliams Paul Anthony · SVP, Products Business9,397 sh
  • Mar 5, 26tax coverGlessner Coleen · EVP, Quality & Ethics, and CPL8,199 sh
🐶 Hiring Signal
No open roles indexed yet — view Emergent BioSolutions Inc. jobs →

News

  • Sarepta pushes back Elevidys timeline; Emergent lays off 90 staffers
    🗓️ Sarepta Therapeutics delays readout of non-ambulatory Elevidys study: The company previously said the study would read out by year end, but reported in its Wednesday earnings that 12-week data are
    endpoints · 14d ago
  • Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring
    Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”
    fiercebiotech · 15d ago
identifiers
ticker
$EBS
SEC CIK
0001367644
country
US
source
sec_tickers
top tags
Infectious Disease7
mentioned in
2news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?